At Emmes Group, numbers tell a story of lasting impact. For nearly five decades, we’ve supported the world’s most complex clinical trials with scientific rigor, global reach, and cutting-edge technology. Our key metrics reflect not only the scale of our operations, but also the trust placed in us by leading sponsors, government agencies, and researchers around the world. These numbers are more than stats—they represent our commitment to uncovering the truth behind medical innovation.
1977
Founded
1981
Longest running client engagement
2,150+
Phase I,II, III, and IV clinical trials In 90+ countries
32,000
Clinical trial sites
98%
Client retention rate
30 million+
eCRF pages
200+
Study data tabulation model (SDTM) studies
434+
Publications in scientific journals since 1916
250 million+
Data points captured across 1 million+ trial subjects
Global Health Impact
Delivering science where it matters most.
Emmes Group has spent nearly five decades turning rigorous science into real-world impact. From pandemic response to chronic disease prevention and equitable global access, our work has shaped public health policy, enabled therapeutic breakthroughs, and improved lives around the world.
- Clinical trial partner in every major global health crisis since the 1980s, including HIV, Ebola, Zika, and COVID-19
- Coordinating center for AREDS and AREDS2, landmark studies that led to a globally adopted supplement for age-related macular degeneration, benefiting ~30 million people
- Partner in the nOPV2 program with the Gates Foundation — contributing to 1.2B doses delivered across 35 countries, preventing vaccine-derived polio outbreaks
- Support for an mRNA COVID-19 vaccine trial in Sub-Saharan Africa, extending vaccine access to underserved communities
- Data Coordinating Center for the NIH’s POP02 pediatric COVID-19 study, providing critical insight into MIS-C and SARS-CoV-2 in children
- Clinical Coordinating Center for the National Institute on Drug Abuse (NIDA) Clinical Trials Network, helping improve treatment options for substance use disorders nationwide
- Longstanding partnerships with 11 major NIH centers, advancing research in addiction, neurodegeneration, maternal health, pediatrics, and health equity
- Over 16,000 patients enrolled in cell and gene therapy trials, helping drive progress in rare and life-threatening diseases
“The impact of this work is profound—providing a scientifically validated approach to slowing the progression of AMD, and improving quality of life for millions of patients worldwide.”
Emmes Team Member
AREDS2 Study